The 5 most-viewed articles by Cardiology Today’s Intervention readers in October

Cardiology Today’s Intervention has compiled a list of the top five stories posted to Healio.com/Cardiac-Vascular-Intervention in the month of October.

This month, Cardiology Today’s Intervention readers were most interested in the FDA approval of the HawkOne directional atherectomy device, results of the NOBLE and BIO-RESORT trials presented at TCT, effects of vorapaxar in treating patients with peripheral artery disease, the results of the PROPHET-II study, and much more.

Smaller-size directional atherectomy system for PAD receives FDA clearance
Medtronic announced that a smaller size of its directional atherectomy device has been cleared by the FDA to be used in patients with PAD. Read More

NOBLE: CABG shows better clinical outcomes for treatment of left main CAD vs. PCI

WASHINGTON — PCI with a drug-eluting stent was inferior to CABG for the outcome of MACCE at 5 years, according to data presented at TCT 2016 and published in The Lancet. Read More

Biodegradable polymer DES noninferior to durable polymer DES at 1 year

WASHINGTON — Two very thin strut biodegradable polymer drug-eluting stents were noninferior to a durable polymer DES and showed favorable clinical outcomes in an all-comers population with CAD in the BIO-RESORT (TWENTE III) trial. Read More

Vorapaxar reduces peripheral revascularization in patients with PAD

Among patients with PAD, the use of vorapaxar appears to reduce peripheral revascularization in a manner that is directionally consistent across procedure type and indication, according to recent findings. Read More

Ulnar compression lowers radial artery occlusion risk after transradial access

Among patients undergoing diagnostic cardiac catheterization using transradial access, the use of prophylactic ipsilateral ulnar compression during radial artery hemostasis safely and effectively prevents radial artery occlusion, according to findings from the PROPHET-II study. Read More